COMMUNIQUÉS West-GlobeNewswire

Autonomix Medical Announces Release of New CEO Corner Segment Highlighting Global Scientific and Clinical Recognition of Platform Technology
10/06/2026
Access the segment here THE WOODLANDS, TX, June 10, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve- [...]
Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial
10/06/2026
The shipment of naturally derived psilocybin, comprising both biomass and 5mg capsules, supports a planned Phase 2 clinical trial in the United Kingdom and was completed under export authorization from Health Canada and [...]
Nexalin Technology Reports Compelling Clinical Trial Results in Brazil to Support Product Launch. Trial Demonstrates 77.8% Anxiety Response Rate and Durable Benefits Across Depression, Insomnia and Quality of Life as Company Advances Brazilian Sales Plan.
10/06/2026
Study using Nexalin’s proprietary DIFS ™ 15 mA 77.5 Hz treatment platform demonstrated rapid, large-magnitude improvements in anxiety and depression with benefits maintained at 8-week follow-up Results further validate [...]
MAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 THIO-101 Expansion Trial
10/06/2026
Additional data from MAIA’s THIO-101 expansion may further support an accelerated approval filing with the FDA Potential breakthrough therapy holds substantial commercial opportunity in a projected $70 billion global [...]
Urteste S.A. enrolls the first patient in the Panuri test clinical study
10/06/2026
Urteste S.A. enrolls the first patient in the Panuri test clinical study Gdańsk, Poland – 10 June 2026 – Urteste S.A. (Warsaw Stock Exchange: URT), a company developing innovative technology for the detection of cancer [...]
CONVOCATION A UNE ASSEMBLEE GENERALE EXTRAORDINAIRE D’IBA SA
10/06/2026
- - LUNDI 29 JUIN 2026 A 11H00 - - Cher Actionnaire, Le quorum requis pour la délibération et le vote sur les sujets à l'ordre du jour de l’assemblée générale extraordinaire des actionnaires de la Société qui était [...]
Beacon Biosignals Unifies Brands, Bringing CleveMed and SleepView® Under the Beacon Name
10/06/2026
Beacon expands home sleep diagnostics with EEG-enabled testing through Waveband, building on CleveMed's established clinical and operational foundation. BOSTON, June 10, 2026 (GLOBE NEWSWIRE) -- Beacon Biosignals today [...]
DataFirst, Inc. and Konica Minolta Healthcare Announce Partnership to Deliver Advanced Interoperability and DICOM Routing Solutions for the Healthcare Enterprise
10/06/2026
WAYNE, N.J. and RALEIGH, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- DataFirst and Konica Minolta Healthcare Americas, Inc. today announced the launch of superior interoperability solutions with Exa® PACS|RIS and Exa® [...]
Bluesight Awarded Pharmacy Technology Solutions Agreement with Premier, Inc.
10/06/2026
Alexandria, VA, USA, June 10, 2026 (GLOBE NEWSWIRE) -- Bluesight , the leader in hospital intelligence solutions, has been awarded a national group purchasing agreement for Pharmacy Technology Solutions with Premier, [...]
DeepHealth Launches Reporting Pro, Bringing AI Automation to Radiology Reporting
10/06/2026
New solution integrates speech recognition, clinical AI findings, measurements, AI-generated impressions and quality assurance SOMERVILLE, Mass., June 10, 2026 (GLOBE NEWSWIRE) -- DeepHealth, Inc., a global leader in AI [...]
Tilray Medical Germany Launches ARX™, a New Premium Medical Cannabis Brand Cultivated in Germany
10/06/2026
New Brand Combines Proven Genetics, German Cultivation Expertise, and Rigorous Quality Standards to Support Patients and Healthcare Professionals Across Germany NEUMÜNSTER, Germany, June 10, 2026 (GLOBE NEWSWIRE) -- [...]
Italfarmaco Announces Health Canada Acceptance and Priority Review of New Drug Submission for Givinostat as a Duchenne Muscular Dystrophy Treatment
10/06/2026
Health Canada Priority Review targets an expedited 180-day review period for givinostat, reflecting Italfarmaco’s commitment to Canadian DMD community NDS is based on Italfarmaco’s Phase 3 EPIDYS trial data [...]
Reacta Healthcare Receives Extended MHRA Pharmaceutical Manufacturer’s Licence and GMP Certificate
10/06/2026
DEESIDE, United Kingdom, June 10, 2026 (GLOBE NEWSWIRE) -- Reacta Healthcare, a leading developer and manufacturer of pharmaceutical-grade oral food challenge (OFC) products for food allergy diagnostics, today announces [...]
Italfarmaco annonce l’acceptation du dépôt et l’examen prioritaire par Santé Canada pour la présentation de drogue nouvelle du givinostat dans le traitement de la dystrophie musculaire de Duchenne
10/06/2026
L’examen prioritaire de Santé Canada vise un délai accéléré de 180 jours pour l’examen du givinostat, reflétant l’engagement d’Italfarmaco envers la communauté canadienne touchée par la dystrophie musculaire de Duchenne [...]
Vara receives CE mark for tomosynthesis AI - extending Europe’s leading screening-grade AI portfolio to 3D
10/06/2026
BERLIN, June 10, 2026 (GLOBE NEWSWIRE) -- Vara, the AI company powering more than half of Germany’s organized breast cancer screening program, today received CE class 2b marking under EU MDR for its tomosynthesis (3D [...]
IBA annonce une collaboration de recherche visant à renforcer les preuves sur la valeur de la protonthérapie
10/06/2026
Louvain-la-Neuve, Belgique, le 10 juin 2026 – IBA (Ion Beam Applications S.A., EURONEXT), leader mondial des technologies d’accélérateurs de particules et premier fournisseur mondial de solutions de protonthérapie pour [...]
Nxera Joins OpenFold AI Research Consortium Alongside Leading Global Pharmaceutical and AI Companies to Accelerate AI-enabled Drug Discovery
10/06/2026
Tokyo, Japan and Cambridge, UK, 10 June 2026 – Nxera Pharma Co., Ltd. (“Nxera” or the “Company”)　announces that it has joined OpenFold, a non-profit AI research consortium that promotes the development of open-source AI [...]
Cytospire Therapeutics Appoints Samit Hirawat, M.D., as Non-Executive Director
10/06/2026
Dr Hirawat i s the former CMO and Head of Global Drug Development at Bristol Myers Squibb and former EVP and Head of Oncology Development at Novartis Augments Cytospire’s clinical development experience as Cytospire [...]
CONNECTA Therapeutics Initiates Phase IIa Clinical Trial of CTH120, a First-in-Class Neuroplasticity Modulator, in Fragile X Syndrome
10/06/2026
Builds on positive Phase I safety data and represents a key value-inflection milestone for the Company Advances a potentially disease-modifying approach for fragile X syndrome, a condition with no approved targeted [...]

Pages